Richard Coles, Mounjaro, and what his experience shows about weight-loss treatment

You heard Richard Coles talk about Mounjaro and started wondering

That's a reasonable place to be. When someone well-known and well-liked describes a personal health decision in honest terms, it shifts the conversation. Suddenly a medicine that felt clinical and remote becomes something real people are using. Searches for Mounjaro spiked noticeably after Richard Coles discussed his experience, and many of the people searching weren't just curious, they were wondering whether it might apply to their own situation.

The short answer is: it might. Mounjaro is licensed in the UK for adults managing their weight, and a growing number of people access it privately through regulated online pharmacies. But a celebrity's account, however candid, can only tell you so much. It tells you the medicine exists. It tells you someone found it worth talking about. It can't tell you whether it's right for you, what dose you'd need, or whether your medical history makes it suitable. Those questions belong to a prescriber.

Worth noting, too, that Richard Coles's openness reflects something broader: weight is increasingly understood as a health condition shaped by biology, hormones and genetics rather than a simple matter of eating less. The medicines now available reflect that shift in understanding.

What tirzepatide actually does, the science behind Richard Coles's treatment

Mounjaro's active ingredient is tirzepatide, and it works differently from older weight-loss medicines. It activates two gut-hormone receptors simultaneously (GIP and GLP-1) both of which play roles in appetite regulation and blood-sugar control. The result is a meaningful reduction in hunger and a slowing of how quickly the stomach empties, which makes meals feel more satisfying for longer.

The evidence base is substantial. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults using tirzepatide 15mg lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased activity. That's a level of effect that had previously only been seen with bariatric surgery in many patients. The trial enrolled thousands of adults, and the results held across the programme as a whole.

The NHS tirzepatide medicines page gives a clear, patient-level overview of how the medicine works, its common side effects, and what to watch for. It's a useful first stop before any consultation. You can also read more about the broader evidence and licensing on our tirzepatide overview.

Who Mounjaro is actually licensed for, and what the clinical assessment covers

Licensing criteria matter because they define the population in whom the medicine has been studied and shown to be safe and effective. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above if they have at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

A BMI figure on its own never tells the whole story. A prescriber will also look at your medical history, any medicines you're currently taking, and whether there are any contraindications, a history of pancreatitis, for example, or certain thyroid conditions would require careful discussion. Pregnancy, breastfeeding and trying to conceive are situations where Mounjaro is not recommended. It is not licensed for anyone under 18.

Treatment starts at a low 2.5mg dose. That starting dose exists to let your system adjust gradually rather than to produce immediate weight loss, titration happens over several weeks under clinical guidance. For a fuller picture of how doses progress, our Mounjaro dose chart walks through the typical schedule. Questions about what to expect from the titration process are also covered on our FAQs page.

On the cost side, private treatment prices have shifted since Eli Lilly adjusted its UK list price in September 2025, context on what that means in practice is on our Mounjaro price increase page.

Side effects, safety and what to be aware of before starting

Richard Coles's public account didn't dwell on side effects, which is understandable, nobody leads with the difficult parts. But any honest account of Mounjaro needs to include them. The most common are gastrointestinal: nausea, loose stools, constipation, indigestion, and occasionally vomiting. These tend to be most noticeable in the early weeks or after a dose increase, and many people find they settle as the body adjusts.

Less commonly, more serious effects can occur. The MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that radiates to the back, with or without vomiting, should prompt urgent medical attention rather than waiting to see if it passes. Any suspected side effect can be reported through the MHRA Yellow Card scheme, and our guide to reporting with Yellow Card explains the process. If you pick up a cold or minor illness while on treatment, it's also worth knowing how that can interact, our page on being unwell on Mounjaro covers the practical steps.

Some people find the first few weeks of treatment coincide with a busy routine, a parent squeezing their 12pm order deadline in before the school run, or a shift worker trying to keep injections on a consistent day. These are real logistics, and a good prescriber will help you think through them.

If you're ready to find out whether Mounjaro could be right for your situation, our prescribers are available to review your consultation the same day it's submitted. Speak to our prescribers to get started with a free clinical assessment.